NICE reconsiders esketamine for depression
BMJ 2020; 370 doi: https://doi.org/10.1136/bmj.m3479 (Published 04 September 2020) Cite this as: BMJ 2020;370:m3479
- Elisabeth Mahase
- The BMJ
The National Institute for Health and Care Excellence (NICE) has launched a second consultation on the use of esketamine for treatment resistant depression, after feedback showed that it could benefit some patients.
Guidance published in January 2020 did not recommend esketamine for treatment resistant depression and said that the drug should not be made available on the NHS because of uncertainties over its clinical efficacy and cost effectiveness.1
However, NICE has now said that a second consultation is required, as “comments from the first consultation suggested esketamine may be used in …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.